Access and Accelerate Grant Program
Access and Accelerate Grant Program supports early-stage Massachusetts life science companies with specialized commercialization expertise to reduce risk and advance innovations toward market and patients.
Funder: Massachusetts Life Sciences Center
Due Dates: October 30, 2026, at 1 p.m. EST (Q4 deadline) | January 2027 (Q1 application period) | March 2027 (Q2 application period)
Funding Amounts: Typically $75,000–$100,000; up to $150,000 in non-dilutive funding for projects of approximately 6–12 months
Summary: Supports early-stage Massachusetts life science companies with specialized expertise to reduce commercialization risk and advance innovations toward market and patients.
Key Information: Q4 2026 funding is restricted to medical device/MedTech market landscape analysis supporting a path to payer coverage.
Description
The Massachusetts Life Sciences Center (MLSC) runs Access and Accelerate to help early-stage Massachusetts life science companies overcome commercialization barriers that are difficult to finance through traditional investment or research grants. Rather than traditional R&D, it supports specialized expertise, market validation, regulatory and reimbursement planning, manufacturing preparation, and other work needed to attract follow-on investment and reach patients.
The program runs quarterly, with each cycle targeting a different sector and eligible use of funds. Its broader scope includes therapeutics, diagnostics, medical devices, digital health, research tools, platform technologies, and enabling technologies. The Q4 2026 cycle specifically funds comprehensive market landscape analysis for medical device/MedTech companies, helping startups understand payer coverage and reimbursement earlier in product development.
